← All Evommune, INC filings

Evommune, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
EVMN
Evommune, INC
10-K: Evommune Reports Positive Phase 2a EVO301 AD Results, IPO Fuels Growth
Evommune, a clinical-stage biotechnology company, reported positive Phase 2a results for EVO301 in atopic dermatitis and detailed its financial position following a November 2025 IPO and a February 2026 private placement.